Company / Shareholders' Equity
Zenas BioPharma, Inc. Shareholders' Equity History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$242.1M
FY2025
5-year range
-$225.7M / $242.1M
FY2023-FY2025
Trend
+207.3%
vs FY2024
Sector context
#149 of 213
Health Care
What the data says
Shareholders' Equity changed +207% YoY in FY2025, a notable deviation from the 2-year average annual change of +104%.
Based on SEC 10-K filings.
$242M in FY2025.
Improved from -$226M to $242M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#149 of 213 in Health CareTop 70% of 213This company $242.1M Sector average $2.5B
▼
-90.5% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 207.3% year-over-year.
- Ranks #149 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $242.1M | +207.3% |
| FY2024 | -$225.7M | +0.0% |
| FY2023 | -$225.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026